AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax

Authors

Soon Khai Low, Rochester Regional HealthFollow
Suparna Nanua, Rochester Regional HealthFollow
Mehul Patel, Rochester Regional HealthFollow
Anne S. Renteria, Rochester Regional HealthFollow

Department

Internal Medicine

Document Type

Article

Publication Title

Leukemia Research Reports

Abstract

A patient with history of myelodysplastic syndrome (MDS) presented with multifocal pneumonia and was found to have Philadelphia chromosomepositive (Ph+) acute myeloid leukemia (AML). A tyrosine kinase inhibitor (TKI) was added to decitabine and venetoclax combination, providing a molecular and cytogenetic complete response despite additional cytogenetic and molecular abnormalities. She remains in remission after eleven cycles of treatment. Our report describes the tolerability and success of a triplet regimen that incorporates a TKI to a backbone of decitabine and venetoclax in a patient with high-risk disease and with significant comorbidities.

First Page

100333

DOI

10.1016/j.lrr.2022.100333

Volume

17

Publication Date

6-22-2022

PubMed ID

35782581

Recommended Citation

Low, S. K., Nanua, S., Patel, M., & Renteria, A. S. (2022). AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax. Leukemia Research Reports, 17, 100333. https://doi.org/10.1016/j.lrr.2022.100333